Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.57 Consensus Price Target from Analysts

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has earned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $16.5714.

FOLD has been the subject of a number of research analyst reports. Zacks Research raised shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Morgan Stanley upgraded Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research report on Thursday, July 17th. Finally, Needham & Company LLC upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a report on Thursday, September 18th.

Insider Buying and Selling

In other news, insider David Michael Clark sold 25,643 shares of Amicus Therapeutics stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $9.51, for a total transaction of $243,864.93. Following the transaction, the insider owned 322,618 shares in the company, valued at approximately $3,068,097.18. The trade was a 7.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On Amicus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Stephens Inc. AR increased its position in Amicus Therapeutics by 27.4% during the 1st quarter. Stephens Inc. AR now owns 13,655 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 2,938 shares during the period. Stephens Investment Management Group LLC bought a new position in Amicus Therapeutics in the 1st quarter valued at approximately $4,998,000. Rice Hall James & Associates LLC boosted its holdings in shares of Amicus Therapeutics by 46.6% during the 1st quarter. Rice Hall James & Associates LLC now owns 2,010,104 shares of the biopharmaceutical company’s stock valued at $16,402,000 after acquiring an additional 639,024 shares in the last quarter. Edgestream Partners L.P. acquired a new stake in shares of Amicus Therapeutics during the first quarter valued at about $477,000. Finally, Massachusetts Financial Services Co. MA boosted its position in Amicus Therapeutics by 0.3% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 3,276,371 shares of the biopharmaceutical company’s stock worth $26,735,000 after buying an additional 8,996 shares during the period.

Amicus Therapeutics Stock Down 0.4%

FOLD stock opened at $9.38 on Tuesday. The firm’s 50-day simple moving average is $8.42 and its 200 day simple moving average is $7.15. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92. The stock has a market cap of $2.89 billion, a PE ratio of -78.16 and a beta of 0.66. Amicus Therapeutics has a fifty-two week low of $5.51 and a fifty-two week high of $10.43.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. The company had revenue of $169.06 million during the quarter, compared to analyst estimates of $165.24 million. Amicus Therapeutics had a negative net margin of 6.67% and a negative return on equity of 5.07%. The business’s revenue for the quarter was up 19.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.10 EPS. Amicus Therapeutics has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Amicus Therapeutics will post 0.15 EPS for the current year.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.